Skip to main content
. Author manuscript; available in PMC: 2012 Jan 7.
Published in final edited form as: Nature. 2011 Jun 15;475(7354):91–95. doi: 10.1038/nature10130

Figure 2. BDNF translation in antidepressant effects of NMDAR antagonists.

Figure 2

a, Immobility in FST following acute ketamine (3.0 mg/kg). At 30-min, ANOVA F1,35=17.13, P=0.0002 for drug, F1,35=7.57, P=0.0093 for genotype-drug interaction, multiple comparisons with t-test (*P<0.05). At 24-hr, in a separate cohort, ANOVA F1,29=3.77, P=0.0619 for treatment, multiple comparisons (*P<0.05) (n=7-12/group). b, Densitometric analysis of BDNF (normalized-GAPDH) in hippocampus following ketamine (3.0 mg/kg) or MK801 (0.1 mg/kg). 30-min., ANOVA F2,12=6.77, P=0 .0108 for treatment, Bonferroni post-hoc test *P<0.05. 24-hrs, no significance (n=5-6/group). c, Anisomycin and actinomycinD protocol. d, Immobility at 30-min., ANOVA F1,34=11.83, P=0.0016 for treatment and F1, 34 = 10.91, P =0.0023 for treatment-inhibitor interaction, multiple comparisons (*P<0.05)(n=8-10/group). e, Immobility at 24 hrs, ANOVA F1, 31=9.34, P =0.0046 for treatment, multiple comparisons (*P<0.05)(n=8-10/group). f, Immobility of WTs given vehicle or NMDA (75 mg/kg), tested 30-minutes later in FST. g, Immobility of WTs given NBQX (10 mg/kg) or PTX (1.0 mg/kg), tested 30-minutes later in FST. h, Immobility of WTs given vehicle, ketamine (3.0 mg/kg), ketamine+NBQX (10 mg/kg), tested 30-minutes later in FST. ANOVA F2,26=8.226, P<0.0019, Bonferroni post-hoc analysis shows ketamine effect reversed by NBQX, *P<0.05. i, Densitometric analysis of p-mTOR (normalized-mTOR) in hippocampus 30-minutes after vehicle or ketamine.